1012341-54-6

Basic information

• Product Name: (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid
• Synonyms: (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid;LCZ 696 Impurity F;Sacubitril Impurity 1;LCZ704;(2S,4R)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid;LCZ-696 Impurity 18;LCZ-696 Impurity 35;(αS,γR)-γ-[[(1,1-Dimethylethoxy)carbonyl]amino]-α-methyl-[1,1-biphenyl]-4-pentanoic Acid
• CAS NO: 1012341-54-6
• Molecular Formula: C23H29NO4
• Molecular Weight: 383.48066
• Product Categories: LCZ696
• Mol File: 1012341-54-6.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 582.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.115±0.06 g/cm3(Predicted)
• PKA: 4?+-.0.23(Predicted)
• CAS DataBase Reference: (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid(1012341-54-6)
• EPA Substance Registry System: (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid(1012341-54-6)

Safety Data

• Hazardous Substances Data: 1012341-54-6(Hazardous Substances Data)

Usage

Uses

(αS,?γR)?-γ-?[[(1,?1-?Dimethylethoxy)?carbonyl]?amino]?-?α-?methyl-?[1,?1''-?biphenyl]?-?4-?pentanoic Acid is a useful synthetic intermediate.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1394050-22-6 [(R)-1-(biphenyl-4-yl)-methyl-2-(2,2,5-trimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-ethyl]-carbamic acid t-butyl ester 
• 1383026-42-3 [(S)-2-biphenyl-4-yl-1-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-ylmethyl)ethyl]carbamic acid t-butyl ester 
• 1383026-37-6 [(R)-1-biphenyl-4-ylmethyl-2-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-2-oxoethyl]carbamic acid t-butyl ester 
• 128779-47-5 (2R)-3-(biphenyl-4-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 108-91-8 cyclohexylamine 
• 149709-68-2 (R)-5-(biphenyl-4-yl)-4-tert-butoxycarbonylamino-2-methylpent-2-enoic acid 
• 1174130-80-3 (R)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylenepentanoic acid 
• 149709-59-1 ethyl 5-(4-<1,1'-biphenyl>yl)-4-<<(1,1-dimethylethoxy)carbonyl>amino>-2-methyl-2-pentenoate 
• 149709-58-0 (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino><1,1'-biphenyl>-4-propanal 
• 1213855-60-7 methyl (R)-3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 1426129-50-1 N-[(1R)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester 
• 149818-98-4 methyl (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino><1,1'-biphenyl>-4-propanoate 

Downstream Products

• 1038924-71-8 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid hydrochloride 
• 149709-60-4 ethyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoate 
• 1174130-83-6 (2R,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid triethylammonium salt 
• 1174131-27-1 (2R,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid methyl ester 
• 1174131-28-2 (2S,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid methyl ester 
• 1174130-82-5 (2R,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid diisopropylethylammonium salt 
• 149709-61-5 (2S,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid ethyl ester 
• 1174130-84-7 (2R,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid sodium salt 
• 149690-05-1 α-ethyl (αR,γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate monosodium salt 
• 1257265-45-4 1-((1S,3R)-1-biphenyl-4-ylmethyl-3-carboxybutylcarbamoyl)-1H-pyrazole-3-carboxylic acid 
• 1257265-46-5 1-((1S,3R)-3-benzyloxycarbonyl-1-biphenyl-4-ylmethylbutylcarbamoyl)-1H-pyrazole-3-carboxylic acid 
• 1257266-14-0 (2R,4S)-5-biphenyl-4-yl-4-isocyanato-2-methylpentanoic acid benzyl ester 
• 1257265-29-4 6-((1S,3R)-1-biphenyl-4-ylmethyl-3-carboxybutylcarbamoyl)-4-oxo-4H-pyran-2-carboxylic acid 
• 1257265-30-7 6-((1S,3R)-3-benzyloxycarbonyl-1-biphenyl-4-ylmethylbutylcarbamoyl)-4-oxo-4H-pyran-2-carboxylic acid 

Relevant articles and documents

Preparation method of sacubitril valsartan sodium

The invention provides a preparation method of sacubitril valsartan sodium, and belongs to the field of medical chemistry. The preparation method comprises the following steps: by using a compound S309A03 as a raw material, carrying out hydrogenation reaction to generate a compound BPA08, reacting the compound BPA08 in ethanol to generate a compound SAC01, reacting the compound SAC01 with succinicanhydride to generate a compound SAC02, optionally reacting the compound SAC02 with sodium hydroxide, and reacting the compound SAC03 with calcium chloride to generate a compound SAC04; and subjecting the compound SAC04 to acid treatment to obtain a compound YJX01, and enabling the compound YJX01 to react with VST in a single solvent in the presence of sodium hydroxide to prepare the compound YJX02. The preparation method disclosed by the invention is simple to operate, the time required by the process is reduced, the total yield of the process route is greatly improved, an unexpected technical effect is obtained, impurities in the process are removed, and a product with higher purity is obtained. The method has mild process conditions and easily available raw materials, and is suitable for industrial amplification.

Substituted ferrocenyl diphosphine homogeneous catalyst ligand

The invention provides a substituted ferrocenyl diphosphine homogeneous catalyst ligand formula I compound. Further, the formula I compound is a metal complex ligand of a homogeneous hydrogenation catalyst. The catalyst ligand is easy to synthesize, convenient to post-treat and easy for industrial production, and very high activity, productivity and enantioselectivity can be obtained by using thecatalyst. The compound is shown in the specification.

Preparation method of sacubitril intermediate

The invention relates to a preparation method of a sacubitril intermediate, and belongs to the technical field of drug intermediate synthesis. The problems that existing operation is large in difficulty and not easy to control are solved. In the presence of a nickel salt catalyst and (R,R)-(-)-N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine, a compound (E)-(R)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpent-2-enoic acid represented by formula II and ammonium formate are mixed in an alcohol solvent and undergo an asymmetric reduction reaction to obtain the corresponding sacubitril intermediate compound represented by formula I. The method does not need to be required to be in an inert atmosphere during production, and is more beneficial to operation. The cost of the raw materials is effectively reduced, and the effect of high yield can still be achieved.